{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:19:51Z","timestamp":1790785191515,"version":"4.1.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"S2","license":[{"start":{"date-parts":[[2010,10,16]],"date-time":"2010-10-16T00:00:00Z","timestamp":1287187200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1007\/s10072-010-0438-7","type":"journal-article","created":{"date-parts":[[2010,10,14]],"date-time":"2010-10-14T23:52:40Z","timestamp":1287100360000},"page":"265-269","source":"Crossref","is-referenced-by-count":37,"title":["Treatment options of cognitive impairment in multiple sclerosis"],"prefix":"10.1007","volume":"31","author":[{"given":"Francesco","family":"Patti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmela","family":"Leone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"D\u2019Amico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,10,16]]},"reference":[{"issue":"3","key":"438_CR1","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/00019052-200306000-00006","volume":"16","author":"JA Bobholz","year":"2003","unstructured":"Bobholz JA, Rao SM (2003) Cognitive dysfunction in multiple sclerosis: a review of recent developments. Curr Opin Neurol 16(3):283\u2013288","journal-title":"Curr Opin Neurol"},{"issue":"10","key":"438_CR2","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1001\/archneur.58.10.1602","volume":"58","author":"MP Amato","year":"2001","unstructured":"Amato MP, Ponziani G, Siracusa G, Sorbi S (2001) Cognitive dysfunction in early-onset multiple sclerosis: a reappraisal after 10\u00a0years. Arch Neurol 58(10):1602\u20131606","journal-title":"Arch Neurol"},{"issue":"9","key":"438_CR3","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1001\/archneurol.2009.174","volume":"66","author":"M Calabrese","year":"2009","unstructured":"Calabrese M et al (2009) Cortical lesions and atrophy associated with cognitive impairment in relapsing\u2013remitting multiple sclerosis. Arch Neurol 66(9):1144\u20131150","journal-title":"Arch Neurol"},{"issue":"5","key":"438_CR4","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1212\/WNL.41.5.692","volume":"41","author":"SM Rao","year":"1991","unstructured":"Rao SM, Leo GJ, Ellington L, Nauertz T, Bernardin L, Unverzagt F (1991) Cognitive dysfunction in multiple sclerosis. II. Impact on employment and social functioning. Neurology 41(5):692\u2013696","journal-title":"Neurology"},{"issue":"3","key":"438_CR5","first-page":"72","volume":"10","author":"MP Amato","year":"2003","unstructured":"Amato MP, Zipoli V (2003) Clinical management of cognitive impairment in multiple sclerosis: a review of current evidence. Int MS J 10(3):72\u201383","journal-title":"Int MS J"},{"key":"438_CR6","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1177\/1352458508096684","volume":"15","author":"F Patti","year":"2009","unstructured":"Patti F (2009) Cognitive impairment in multiple sclerosis. Mult Scler 15:2\u20138","journal-title":"Mult Scler"},{"issue":"7","key":"438_CR7","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1177\/1352458509105544","volume":"15","author":"F Patti","year":"2009","unstructured":"Patti F et al (2009) Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study. Mult Scler 15(7):779\u2013788","journal-title":"Mult Scler"},{"issue":"6","key":"438_CR8","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/1531-8249(200012)48:6<885::AID-ANA9>3.0.CO;2-1","volume":"48","author":"JS Fischer","year":"2000","unstructured":"Fischer JS, Priore RL, Jacobs LD, Cookfair DL, Rudick RA, Herndon RM et al (2000) Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group. Ann Neurol 48(6):885\u2013892","journal-title":"Ann Neurol"},{"key":"438_CR9","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0140-6736(07)61194-5","volume":"370","author":"L Kappos","year":"2007","unstructured":"Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, Montalb\u00e1n X, Barkhof F et al (2007) Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 370:389\u2013397","journal-title":"Lancet"},{"key":"438_CR10","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1177\/1352458509350309","volume":"16","author":"F Patti","year":"2010","unstructured":"Patti F, Amato MP, Bastianello S, Caniatti L, Di Monte E, Ferrazza P, Goretti B, Gallo P, Brescia Morra V, COGIMUS Study Group et al (2010) Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing\u2013remitting multiple sclerosis. Mult Scler 16:68","journal-title":"Mult Scler"},{"issue":"9","key":"438_CR11","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1212\/01.WNL.0000142989.09633.5A","volume":"63","author":"LB Krupp","year":"2004","unstructured":"Krupp LB, Christodoulou C, Melville P, Scherl WF, MacAllister WS, Elkins LE (2004) Donepezil improved memory in multiple sclerosis in a randomized clinical trial. Neurology 63(9):1579\u20131585","journal-title":"Neurology"},{"issue":"2","key":"438_CR12","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S1474-4422(05)00972-5","volume":"4","author":"MP Amato","year":"2005","unstructured":"Amato MP (2005) Donepezil for memory impairment in multiple sclerosis. Lancet Neurol 4(2):72\u201373","journal-title":"Lancet Neurol"},{"key":"438_CR13","unstructured":"Krupp L, Christodoulou C et al (2010) A multi-center randomized clinical-trial of donezepil to treat memory impairment in multiple sclerosis. AAN, Toronto, S21.004"},{"key":"438_CR14","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1093\/brain\/awg284","volume":"126","author":"MM Parry","year":"2003","unstructured":"Parry MM et al (2003) Potentially adaptive functional changes in cognitive processing for patients with multiple sclerosis and their acute modulation by rivastigmine. Brain 126:2750\u20132760","journal-title":"Brain"},{"issue":"11","key":"438_CR15","first-page":"A112","volume":"72","author":"JF Lovera","year":"2009","unstructured":"Lovera JF et al (2009) Randomized double-blind placebo-controlled trial of memantine 10 mg twice a day for three months as a treatment for cognitive impairment in multiple sclerosis. Neurology 72(11):A112\u2013A112","journal-title":"Neurology"},{"key":"438_CR16","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1212\/01.wnl.0000342388.73185.80","volume":"72","author":"P Villoslada","year":"2009","unstructured":"Villoslada P, Arrondo G, Sepulcre J, Alegre M, Artieda J (2009) Memantine induces reversible neurologic impairment in patients with MS. Neurology 72:1630\u20131633","journal-title":"Neurology"},{"key":"438_CR17","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1001\/archneur.1996.00550020101021","volume":"53","author":"MW Geisler","year":"1996","unstructured":"Geisler MW et al (1996) The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis. Arch Neurol 53:185\u2013188","journal-title":"Arch Neurol"},{"key":"438_CR18","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1177\/1352458506071213","volume":"13","author":"J Lovera","year":"2007","unstructured":"Lovera J et al (2007) Ginkgo biloba for the improvement of cognitive performance in multiple sclerosis: a randomized, placebo-controlled trial. Mult Scler 13:376\u2013385","journal-title":"Mult Scler"},{"issue":"9","key":"438_CR19","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1136\/jnnp.2007.139345","volume":"79","author":"JP Mostert","year":"2008","unstructured":"Mostert JP et al (2008) Effects of fluoxetine on disease activity in relapsing multiple sclerosis: a double-blind, placebo-controlled, exploratory study. J Neurol Neurosurg Psychiatry 79(9):1027\u20131031","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-010-0438-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10072-010-0438-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-010-0438-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T09:11:47Z","timestamp":1559121107000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10072-010-0438-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10,16]]},"references-count":19,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["438"],"URL":"https:\/\/doi.org\/10.1007\/s10072-010-0438-7","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,10,16]]}}}